Librela can start reducing osteoarthritis pain in dogs as early as 7 days after the first injection, but many dogs take longer. Some won’t show clear improvement until about 6 weeks in, which is roughly two weeks after their second monthly dose. The timeline varies significantly from dog to dog, so the first injection alone isn’t always a reliable test of whether the medication will help.
What Happens in the First Week
After your vet gives the injection under the skin, Librela’s active ingredient (bedinvetmab) reaches peak levels in the bloodstream within 4 to 7 days. This is when the earliest responders start showing signs of improvement. You might notice your dog getting up more easily, being more willing to walk, or showing less stiffness after resting. But this quick response isn’t universal. In clinical trials, roughly 47% of dogs met the threshold for treatment success by day 28, meaning more than half hadn’t clearly responded after a full month.
Why the Second Dose Matters
Veterinary guidelines are clear on this point: if your dog shows little or no improvement after the first injection, give it a second month before deciding the drug isn’t working. A second dose one month later can produce a noticeably better response in dogs that seemed like non-responders initially.
Clinical data backs this up. In a study comparing Librela to a traditional anti-inflammatory, dogs showed significantly greater pain reduction at later visits compared to earlier ones. The researchers noted that this pattern of increasing benefit with continued treatment is well established, and expert guidelines recommend treating for at least one to two months before evaluating results. By the second and third months, success rates in trials climbed to roughly 50%, up from the initial month’s numbers.
If your dog still isn’t responding after two doses, that’s the point where your vet will likely recommend exploring other options.
How Librela Reduces Pain
Librela works differently from traditional painkillers like anti-inflammatories. It’s a monoclonal antibody, essentially a lab-engineered protein that targets one specific molecule in the body: nerve growth factor, or NGF.
In a dog with osteoarthritis, damaged joint tissues release NGF, which binds to receptors on nearby nerve endings. This triggers a cascade that makes those nerves increasingly sensitive to pain. The nerve endings essentially get “turned up,” responding more intensely to pressure and movement that wouldn’t normally hurt. NGF also activates immune cells near the joint, causing them to release inflammatory compounds that further amplify the pain signal.
Librela intercepts NGF before it can latch onto those nerve receptors, blocking the whole sensitization process. Because this involves gradually dialing down nerve sensitivity rather than masking pain signals the way a traditional painkiller does, it helps explain why some dogs need more than one dose to see the full benefit. The nerves need time to reset.
How Long Each Dose Lasts
Librela is given once a month as a subcutaneous injection at the vet’s office. The drug’s half-life (the time it takes for half the dose to leave the body) averages about 15 to 19 days in dogs with osteoarthritis, though this varies considerably between individual dogs. Some owners notice their dog’s comfort dipping in the last few days before the next scheduled injection, which lines up with drug levels dropping toward the end of the monthly cycle.
Signs to Watch For
Because dogs can’t tell you they’re feeling better, you’ll need to watch for behavioral changes. The most common signs that Librela is working include more willingness to go on walks or play, less hesitation before jumping onto furniture or into the car, smoother movement when getting up from lying down, and a generally brighter demeanor. Some owners report that their dog seems more like their younger self.
One thing to watch for if Librela does work well: dogs that suddenly feel much better may overdo it. A dog that has been limited by pain for months might want to run, jump, and play at a level their joints aren’t conditioned for. This can lead to soreness or even injury. It’s worth gradually increasing activity rather than letting your dog go all out on a good day.
What the Success Rates Look Like
In a large placebo-controlled U.S. field study, 47.4% of dogs receiving Librela met the criteria for treatment success at day 28, compared to 36.6% on placebo. A separate multinational trial found a 43.5% success rate at day 28, climbing to about 51% by day 56. These numbers represent dogs that crossed a specific clinical threshold for improvement, so some dogs below that cutoff still experienced partial relief.
Comparing Librela head-to-head with meloxicam (a widely used anti-inflammatory), the two performed similarly over a multi-month study. Librela produced an average 19.7-point reduction in a composite pain and mobility score, while meloxicam produced a 17.1-point reduction. The practical advantage of Librela for many owners is that it’s a monthly injection rather than a daily oral medication, and it avoids the kidney and liver concerns that come with long-term anti-inflammatory use.
Not every dog responds to Librela. If your dog falls into the non-responder category after two monthly doses, it likely means that nerve growth factor isn’t the primary driver of their pain, and a different approach will be more effective.